中國生物科技服務(08037.HK):BNCT(硼中子)癌症治療中心項目獲原則准入海南博鰲國際醫療旅遊先行區
格隆匯11月19日丨中國生物科技服務(08037.HK)公吿,於2021年11月17日,公司獲悉中國海南自由貿易港博鰲樂城國際醫療旅遊先行區管理局通過專家評審會議,原則同意由公司作為發起方的BNCT(硼中子)癌症治療中心項目在博鰲樂城先行區進行落地建設及實施。
該項目採用BNCT(硼中子俘獲治療)技術是難治性癌症的新療法,已於2020年在日本正式進入臨牀應用,是目前國際先進的癌症治療手段之一,特別對於多次復發、浸潤性、局部轉移及中晚期難治性病例臨牀優勢顯著。出席評審會議專家同意引進硼中子治療可以滿足癌症患者診療需要,有利於中國腫瘤及癌症防治工作的進步。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.